Inter partes re-examinations at the
USPTO could play a part in reducing
patent values and discouraging R&D
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
@IAM_magazine Congressional action on drug prices in the United States is already putting patents in the spotlight https://t.co/6YkfC0HCJr Read more
@IAM_magazine A welcome 101 boost for software patent owners from CAFC https://t.co/LImetW8GWo Read more
@IAM_magazine Chinese drone maker turns to Microsoft to boost its US portfolio https://t.co/NpvSJrxCJb Read more
@IAM_magazine Fed Circuit weighs in again on 101 with a good result for patent owners https://t.co/LImetW8GWo Read more